NeuroSense Therapeutics publishes CEO shareholder letter on Phase 3 PrimeC plans

Reuters2026/08/13 14:57

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NeuroSense published a CEO shareholder letter outlining delays in securing funding needed to start the Phase 3 PARAGON study of PrimeC in ALS.
FDA clearance received to initiate PARAGON; trial planned to enroll about 300 participants, mainly in the US, with timing tied to financing.
Canada regulatory push advanced; New Drug Submission for PrimeC now targeted for December 2026 following Health Canada pre-NDS discussions.
CEO Alon Ben-Noon cited April investments of USD 200,000 each by him and CFO Or Eisenberg, alongside an existing investor.
Nasdaq compliance efforts include seeking more time, with a proposed reverse split authorization range of 1-for-4 to 1-for-40 if needed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-088851), on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NeuroSense Therapeutics publishes CEO shareholder letter on Phase 3 PrimeC plans

You may also like

Crypto prices